21/12/2023 - Events
Research into immunotherapy for cancer at the Hospital del Mar Medical Research Institute has received a new boost thanks to a donation of 43,250 euros from the Amics de l’Hospital del Mar Foundation. The president of the Amics de l’Hospital del Mar Foundation, Xavier Trias, presented the cheque to the young researchers Marta Bort, Laura Ibáñez and Iván Pérez, on behalf of the research team looking into the Role of Interferon-Gamma in T cell-mediated elimination of breast cancer tumour cells, a project selected through the internal call for proposals "immunotherapy seed". This initiative is aimed at studying, through a proof of concept, some of the molecular mechanisms used by tumour cells to resist immunotherapy, with the goal of improving breast cancer treatments.
07/11/2022 - General information
At the same time, the head of the Haematological Cytology section of the Pathology Service of the Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute, is secretary of the board of directors of the Spanish Group for Haematological Cytology and also holds the same position in the Spanish Group of Myelodysplastic Syndromes.
24/10/2022 - General information
Two of the grants are awarded by SEOM itself and the third by the Spanish Lung Cancer Group. Two research projects from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received three grants of support during the congress of the Spanish Society of Medical Oncology, held in Madrid from October 18 to 21. The two projects will analyze different aspects related to immunological markers in different subtypes of lung cancer and in patients with different behaviors in response to immunotherapy.
20/10/2022 - General information
Ramon Diez-Feijóo Varela and Sílvia Ramos Campoy have received two personal grants to develop different research projects. Two researchers from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received two grants from the Spanish Society of Hematology and Hemotherapy, within the framework of the LXIV congress of the organization, held in Barcelona from October 6 to 8. These are personal grants for one year, worth 36,000 euros, renewable for a second year.
19/10/2022 - Press release
A multicentre study involving hospitals in Spain and Portugal, led by Hospital del Mar, shows that these patients already receive enough radiation to treat the disease when the breast affected by the tumour is irradiated directly. The study monitored more than 400 women. The results indicate that the five-year survival rate and relapses are practically identical between those who underwent specific treatment targeting the nodes located in the armpits and those who only received breast radiation. The findings of the OPTIMAL study have been published in the journal Radiation Oncology and can now be applied to clinical practice. Thanks to this fact, patients will need less radiotherapy and will suffer fewer treatment-related side effects.
17/10/2022 - Institutional news
It will analyse the role the circadian rhythm alteration of intestinal microbiota plays in the development of Alzheimer's disease. The project is one of the sixty selected in the ninth call for applications for these grants, which reward highly innovative projects in nine areas of scientific knowledge and culture. The project by IMIM-Hospital del Mar researcher Patrick-Simon Welz, 'Losing the rhythm: host-microbiota circadian communication in Alzheimer's disease', is one of the 60 projects selected in the ninth edition of the Leonardo grants, awarded by the BBVA Foundation. These grants support highly innovative proposals in various scientific and cultural fields. This year, 884 applications were submitted and evaluated by 85 independent experts divided into nine panels.
17/10/2022 - Institutional news
The Section Chief of the Gastrointestinal Surgery Department at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute became a corresponding member of the RAMC, in a ceremony held on 4 October at the institution's headquarters. Dr. Manuel Pera has been a corresponding member of the Royal Academy of Medicine of Catalonia since 4 October. The appointment was made in a ceremony held at the institution's headquarters, in which the Section Chief of the Surgery Department at Hospital del Mar and coordinator of the Gastroesophageal Carcinogenesis research group at the Hospital del Mar Medical Research Institute (IMIM), gave the speech, 'Improving the quality of care in digestive cancer surgery: the experience of the Spanish EURECCA Oesophagogastric Cancer Registry'. The presentation of the new member was led by Dr. Lluís Grande i Posa, full member of the RAMC and Emeritus Chief of Surgery at Hospital del Mar.
05/10/2022 - Press release
A study led by researchers at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) has determined the role that fibroblasts, the cells that contribute to tissue formation, play in a tumour's ability to generate resistance to the most common biological treatment for HER2. The paper, published in the journal Nature Communications, demonstrates the ability of a new therapy, currently undergoing clinical trials, to promote a potent immune response by binding to the fibroblasts, enabling it to overcome resistance to anti-HER2 therapy in tumours with this cancer cell protection mechanism. To demonstrate this, the researchers created a 3D tumour model in which they were able to check the relationships between all the factors involved.
23/08/2022 - General information
A team from Hospital del Mar and the Hospital del Mar Medical Research Institute has validated the technique involving breast biopsy guided by contrast mammography to visualise suspicious lesions that cannot be observed via ultrasound or mammography. After analysing data from tests performed on 64 women, they have been able to verify that this technique offers the same or better results than the other diagnostic tool used in these cases, magnetic resonance imaging (MRI). The results have been published in the journal European Radiology. In the cases studied, contrast mammography-guided breast biopsy was successful in 95.4% of cases. In only three tests was the visibility of the findings not as expected. In comparison, MRI has a success rate of between 87% and 98%.
Més informació "Usefulness of breast biopsy guided by contrast-enhanced mammography is validated"
12/07/2022 - General information
This is one of the fifteen biomedical projects selected in the CaixaResearch Validate call. In this case, the study led by the researcher from the Hospital del Mar Medical Research Institute seeks effective immunotherapy treatment for breast tumours. The "la Caixa" Foundation is supporting 15 leading biomedical research projects in Spain and Portugal in the CaixaResearch Validate 2022 call. These are early-stage projects that the organisation wants to support to accelerate their arrival on the market, thereby helping them reach patients who may need them. Among those selected is a project led by Dr. Toni Celià-Terrassa, who heads up the Cancer Stem Cells and Metastasis Dynamics laboratory at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact